Search research articles
Contact Us
Filters
Showing results (141-150 of 269) with videos related to
Page
of 27
Sort By:
The American Journal of Gastroenterology
|
October 3, 2002
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
Severine Vermeire, Edouard Louis, An Carbonez, et al.
The New England Journal of Medicine
|
May 5, 2016
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
William J Sandborn, Brian G Feagan, Douglas C Wolf, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 26, 2015
Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease
Geert D'Haens, Mark Löwenberg, Mark A Samaan, et al.
Expert Review of Gastroenterology & Hepatology
|
March 21, 2024
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Rish K Pai, Geert D'Haens, Taku Kobayashi, et al.
Gastroenterology
|
February 14, 2012
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial
Paul Rutgeerts, Gert Van Assche, William J Sandborn, et al.
Journal of Crohn'S & Colitis
|
July 22, 2025
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review
Sophie Vieujean, Bruce E Sands, Remo Panaccione, et al.
Journal of Crohn'S & Colitis
|
November 1, 2024
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies
Raja Atreya, Marc Ferrante, Remo Panaccione, et al.
Journal of Crohn'S & Colitis
|
April 17, 2025
Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis
Bram Verstockt, Dahham Alsoud, Joep van Oostrom, et al.
Alimentary Pharmacology & Therapeutics
|
June 16, 2023
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis
Geert D'Haens, Laurent Peyrin-Biroulet, Daniel J B Marks, et al.
Journal of Crohn'S & Colitis
|
June 17, 2026
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results
Vipul Jairath, Fernando Magro, Marijana Protic, et al.
Page
of 27
Search research articles
Search
Showing results (141-150 of 269) with videos related to
Sort By:
Page
of 27
The American Journal of Gastroenterology
|
October 3, 2002
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
Severine Vermeire, Edouard Louis, An Carbonez, et al.
The New England Journal of Medicine
|
May 5, 2016
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
William J Sandborn, Brian G Feagan, Douglas C Wolf, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 26, 2015
Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease
Geert D'Haens, Mark Löwenberg, Mark A Samaan, et al.
Expert Review of Gastroenterology & Hepatology
|
March 21, 2024
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Rish K Pai, Geert D'Haens, Taku Kobayashi, et al.
Gastroenterology
|
February 14, 2012
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial
Paul Rutgeerts, Gert Van Assche, William J Sandborn, et al.
Journal of Crohn'S & Colitis
|
July 22, 2025
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review
Sophie Vieujean, Bruce E Sands, Remo Panaccione, et al.
Journal of Crohn'S & Colitis
|
November 1, 2024
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies
Raja Atreya, Marc Ferrante, Remo Panaccione, et al.
Journal of Crohn'S & Colitis
|
April 17, 2025
Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis
Bram Verstockt, Dahham Alsoud, Joep van Oostrom, et al.
Alimentary Pharmacology & Therapeutics
|
June 16, 2023
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis
Geert D'Haens, Laurent Peyrin-Biroulet, Daniel J B Marks, et al.
Journal of Crohn'S & Colitis
|
June 17, 2026
Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results
Vipul Jairath, Fernando Magro, Marijana Protic, et al.
Page
of 27